Skip to content
naulon
Not checkedNot checked for notices yet.

Hepatic perihilar amphicrine cholangiocarcinoma: A case report

Thomas W. Czeczok, David J. Schembri-Wismayer, Thomas C. Smyrk and 2 more

Human Pathology: Case Reports · 2018

doi:10.1016/j.ehpc.2018.05.007 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Mixed neuroendocrine nonneuroendocrine neoplasms (MiNEN) are tumors composed of adenocarcinoma and neuroendocrine neoplasm and include collision, combined, and amphicrine. Within the hepatobiliary tree, tumors of this histologic type are extremely rare, particularly the amphicrine type. In this case study, we describe a 63-year-old man with a hepatic hilar amphicrine tumor. An initial diagnosis of neuroendocrine tumor was made based on biopsy (chromogranin and synaptophysin positivity). On resection, the tumor contained histologic features of both adenocarcinoma and neuroendocrine carcinoma. Immunohistochemically, all tumor cells expressed both chromogranin and synaptophysin, keratin 7, and Cam5.2. Mucin production was evident in both components demonstrated by mucicarmine stain. Albumin RNA in situ hybridization (ISH) was positive, supporting hepatic source. The tumor is classified as an amphicrine carcinoma given the dual expression of both adenocarcinoma and neuroendocrine markers in both components. This is the first amphicrine carcinoma of the hepatic hilum reported in the literature. Keywords: Cholangiocarcinoma, Mixed neuroendocrine-nonneuroendocrine carcinoma, Neuroendocrine tumor, Liver, Immunohistochemistry, Hepatobiliary

Abstract licence: CC BY-NC-ND

References18

  1. 6.

17 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.